Abstract:
It was made an analysis of contemporary therapy of migraine, a review of preclinical and
clinical data of a new migraine management, presenting clinical trial results based on the
information from the observation files of patients with chronic migraine. Migraine treatment has
evaluated in the last decade, several new approaches to the treatment of migraine have been
substantially advanced, including selective 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor
agonists, the launch of sumatriptan was later followed by the appearance of a series of new
compounds serotonin agonists, second generation (5-TH B/D): almotriptan, eletriptan,
frovatriptan, naratriptan, zolmitriptan and a new class of drugs 5-HT(1F) receptor agonists,
called third generation, such as LY344864.
A fost efectuată o analiză a terapiei contemporane a migrenei, revizuirea datelor preclinice
şi clinice în managementul migrenei, cu prezentarea rezultatelor studiului clinic în baza fişelor
de observaţie a pacienţilor cu migrenă cronică. Tratamentul migrenei a evoluat în ultimul
deceniu, au fost avansate substanţial multe abordări noi antimigrenoase, inclusiv introducerea
agoniştilor selectivi ai receptorilor 5-hidroxitriptamină 1B/1D (5-HT1B/1D). Lansarea
sumatriptanului a fost ulterior urmată de apariţia unei serii de noi compuşi agonişti
serotoninergici, de generaţia doua (5-TH B/D): almotriptan, eletriptan, frovatriptan, naratriptan,
zolmitriptan şi o nouă clasă de medicamente, de generaţia a treia, agoniştii receptorilor 5-HT
(1F), cum ar fi LY344864.
Description:
Conducător ştiinţific, Veaceslav Gonciar, d.h.m., profesor universitar
Catedra Farmacologie şi Farmacie clinică, USMF „Nicolae Testemiţanu"
